Further Medicare Coverage Approval for DermaPure

Tissue Regenix Group plc

First Coast Service Options Inc. approves Medicare coverage for DermaPure

Now available to c.65% of Medicare beneficiaries

York, 30 July 2015 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that it has further strengthened its position within the post-acute wound care market as Tissue Regenix Woundcare Inc. has received further approval for DermaPure® under Medicare administrator, First Coast Service Options Inc. ("First Coast") whose jurisdiction includes Florida, Puerto Rico and the US Virgin Islands

With this approval, Tissue Regenix Woundcare Inc. increases the number of Medicare beneficiaries to whom DermaPure® is available by 2.5m. With prior approvals from Noridian Health Care Solutions, Palmetto GBA, Novitas Solutions and CGS Administrators within the first seven months of market availability, DermaPure® is now available across 31 States, the US Virgin Islands and Puerto Rico and is accessible to c.65% of the 37m beneficiaries enrolled under the Medicare programme.

The Medicare programme within the United States acts a national insurance programme available to citizens of 65 and over, subsidising healthcare costs and providing access to treatment that may otherwise not be available. This approval by First Coast means that medical establishments under their jurisdiction can now seek reimbursement for the use of DermaPure® in outpatient scenarios.

Antony Odell, CEO of Tissue Regenix Group plc:

"Tissue Regenix continues to make significant progress in securing these critical approvals, not only allowing more patients to benefit from improved clinical outcomes, but demonstrating both the efficacy of the product and the strength of our hybrid commercialisation strategy.

Commercial interest in DermaPure® continues to grow and I look forward to announcing further LCD coverage approvals and expanding commercial payer coverage in due course."

Notes:

Previously announced DermaPure® coverage approvals:

Novitas Solutions: Arkansas, Colorado, Delaware, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, Texas and Washington DC

CGS: Kentucky and Ohio

Noridian Healthcare Solutions: Alaska, Arizona, California, Hawaii, Montana, Nevada, North Dakota, Oregon, South Dakota, Utah, Washington and Wyoming.

Palmetto GBA: North Carolina, South Carolina, Virginia and West Virginia

For Further Information

Tissue Regenix Group Plc: +44 19 0456 7609

Caitlin Pearson

Corporate Communications Officer

c.pearson@tissueregenix.com

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications: +44 207 353 4200

Tom Buchanan

Victoria Huxster

Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.